Antihemophilic factor

Table 11. Properties of Factor VIII (Antihemophilic Factor) and Factor IX Concentrates...

Antihemophilic factor [9001-28-9] (AHF) is a protein found in normal plasma that is necessary for clot formation. It is needed for transformation of prothrombin to thrombin. Administration of AHF by injection or infusion can temporarily correct the coagulation defect present in patients with hemophilia. Antihemophilic factor VIII (Alpha Therapeutic) has been approved by the FDA as replacement therapy in patients with hemophilia B to prevent bleeding episodes, and also during surgery to correct defective hemostasis (178). 

Tissue plasminogen activators Human growth hormone Neuroactive peptides Regulatory peptides Lymphokines Human serum albumin Gamma globulin Antihemophilic factors Monoclonal antibodies... 

Proconvertin, serum prothrombin conversion accelerator (SPCA), cothromboplastin Antihemophilic factor A, antihemophilic globulin (AHG)... 

Antihemophilic factor B, Christmas factor, plasma thromboplastin component (PTC)... 

Elumate-P Antihemophilic factor/von Willebrand factor complex Centeon Pharma Treatment and prevention of bleeding in hemophilia A... 

KoGENate Antihemophilic factor Bayer corporation Treatment of hemophilia A... 

Recombinate Antihemophilic factor Baxter Genetics Institute Hemophilia A... 

Antihemophilic factor Antihemophilic factor is a protein that converts prothrombin to thrombin, and replaces a deficit of endogenic hemophilic factor. It is synthesized by processing human plasma [69-70]. It is used to treat classic hemophilia A and to stop bleeding. Synonyms of this drug are hemophil T, monoclate, cryoblin, and others. 

Antihemophilic Factor [AHF/ Factor VIII] (Monoclate) [Antihemophilic] Uses Classic hemophilia A, von Willebrand Dz Action Provides factor VIII needed to convert prothrombin to thrombin Dose Adults Peds. 1 AHF Unit/kg T factor VIII level 2 Int Units/dL, Units required = (kg) (desired factor VIII T as % nl) X (0.5) prevent spontaneous hemorrhage = 5% nl hemostasis after trauma/surgery = 30% nl head injuries, major surgery, or bleeding = 80-100% nl Caution [C, ] Disp Inj SE Rash, fever, HA, chills, N/V Interactions None EMS None OD Unlikely... 

Blood coagulation factors antihemophilic factor (recombinant) eptacog alfa (activated) factor IX contentrate (human) factor IX (recombinant) moroctocog alfa... 

A. General description The active substance in ReFacto is antihemophilic factor (recombinant), a 1438 amino-acid glycoprotein (approximately 170 kDa) that is produced in engineered Chinese hamster... 

Pharmacokinetics In a pharmacokinetic study of previously treated patients, the circulating mean half-Ufe for ReFacto was 14.5 5.3 hours (range 7.6-27.7 hours), which was not significantly different from plasma-derived antihemophilic factor (human), which had a mean half-life of 13.7 3.4 hours (range 8.8-23.7 hours). Pharmacokinetic studies on 66 patients showed the circulating mean half-life for rAHF (Recombinate) to be 14.4 + 4.9 hours, which was not significantly different from a plasma-derived human antihemophilic factor, which had a mean half-life of 14.0 + 3.9 hours. One study determined a mean clearance of 127 mF min per kg. 

E Role in therapy Antihemophilic factor is indicated for the treatment of bleeding episodes or perioperative treatment in patients with hemophilia A. Prophylactic use has also been advocated for the prevention and/or reduction of bleeding episodes. The largest issue in treatment with antihemophilic factor is the choice of formulations because of the relative risk of viral transmission. Recombinant factor VIII has the lowest risk of transmission of blood-borne viruses, but its use may be limited due to cost and availability. 

H. Other considerations Antihemophilic factor (recombinant) has been designated an orphan product for use in the treatment or prophylaxis of bleeding in hemophilia A, or prophylaxis before surgery. 

---